Patritumab
- Generic Name
- Patritumab
- Drug Type
- Biotech
- CAS Number
- 1262787-83-6
- Unique Ingredient Identifier
- 86780VJI1Q
- Background
Patritumab has been used in trials studying the treatment of LUNG CANCER, Solid Tumors, Neoplasms by Site, Head and Neck Neoplasms, and Non-small Cell Lung Cancer, among others.
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 50
- Registration Number
- NCT06941272
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Conditions
- Breast NeoplasmsBreast Cancer
- Interventions
- First Posted Date
- 2025-01-28
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 372
- Registration Number
- NCT06797635
- Locations
- 🇺🇸
Northwest Cancer Specialists (Compass Oncology) ( Site 8003), Tigard, Oregon, United States
🇺🇸Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003), Billings, Montana, United States
🇺🇸SCRI Oncology Partners ( Site 7000), Nashville, Tennessee, United States
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
- Conditions
- Breast NeoplasmsBreast Cancer
- Interventions
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 81
- Registration Number
- NCT06686394
- Locations
- 🇺🇸
Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053), Greenville, South Carolina, United States
🇰🇷Seoul National University Hospital ( Site 0030), Seoul, Korea, Republic of
🇺🇸Rutgers Cancer Institute of New Jersey ( Site 0052), New Brunswick, New Jersey, United States
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 130
- Registration Number
- NCT06596694
- Locations
- 🇦🇺
Alfred Health ( Site 0102), Melbourne, Victoria, Australia
🇦🇺Austin Health ( Site 0103), Melbourne, Victoria, Australia
🇦🇺One Clinical Research ( Site 0104), Mount Pleasant, Western Australia, Australia
Patritumab Deruxtecan in Patients with Solid Tumor Harboring an NRG1 Fusion
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT06383884
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
- Conditions
- Breast Cancer MetastaticHER2 Low Breast CarcinomaHER2-positive Metastatic Breast CancerAdvanced Breast Cancer
- Interventions
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 152
- Registration Number
- NCT06298084
- Locations
- 🇫🇷
Gustave Roussy Institut, Villejuif, France
HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease
- Conditions
- Solid Tumor, AdultMetastatic Breast CancerAdvanced Non-Small Cell Squamous Lung Cancer
- Interventions
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 60
- Registration Number
- NCT05865990
- Locations
- 🇦🇹
Salzburg Cancer research Institute-Center for Clinical Cancer and Immunology Trials, Salzburg, Austria
🇦🇹Medical University of Vienna, Vienna, Austria
🇪🇸Hospital Universitari Dexeus, Barcelona, Spain
A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Mustafa Khasraw, MBChB, MD, FRCP, FRACP
- Target Recruit Count
- 15
- Registration Number
- NCT05620914
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- SOLTI Breast Cancer Research Group
- Target Recruit Count
- 120
- Registration Number
- NCT05569811
- Locations
- 🇪🇸
Complejo Hospitalario San Pedro de Alcántara, Cáceres, Spain
🇪🇸Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain
🇪🇸Hospital Universitario de Canarias, Tenerife, Islas Canarias, Spain
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
- Conditions
- Nonsquamous Non-small Cell Lung CancerEGFR L858REGFR Exon 19 Deletion
- Interventions
- Drug: Platinum-based chemotherapy
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 586
- Registration Number
- NCT05338970
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇯🇵Kurume University Hospital, Kurume, Japan
🇮🇹Ospedale Santa Maria della Misericordia, Perugia, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.